That comment by Joe must’ve been for Olaregen. Although the K hadn’t provided a clear picture of where they are with revenue, and since making that public comment Joe has explained its unwise to ask for clarification on rev projection for Excellagen. I’d rather just see numbers in the next Q anyway. That will help.